CommunicationThere are many things out of the control of management, such as final ethics approvals from Canadian sites participating in the AKI Phase 2 Study or news flowing from the new Pontiac Trial announced.
As demonstrated time and time again the company continues to fire on all cylinders and routinely releases material news with little to no
impact on the share price or daily volume.
The one area management does control is communication to the markets. This is the area we lack expertise at and need improvement in.
We should hire PeptidePete to draft a comprehensive investor deck outlining the science and all the milestones achieved coupled with why this is an opportunity of a lifetime.
Then we send PeptidePete out to meet with Money Managers, Analysts, Trade shows, High networth Family offices, Big Pharma to present the opportunity to generate buying interest.
Arch is so severely undervalued at this point and nobody knows about the science and the golden opportunity.